Precision Immunotherapy in Pneumonia: Presepsin-Guided Anakinra Significantly Reduces Organ Dysfunction and Mortality
Posted inCritical Care Infectious Diseases news

Precision Immunotherapy in Pneumonia: Presepsin-Guided Anakinra Significantly Reduces Organ Dysfunction and Mortality

The Phase IIa INSPIRE trial demonstrates that early administration of anakinra, guided by the presepsin biomarker, reduces the risk of organ dysfunction by 30% and significantly improves 90-day survival in hospitalized pneumonia patients, marking a major step forward for precision medicine in critical care.
Dual-Action IgY and Cerium Oxide Nanofibrous Dressings Accelerate Scarless Healing in Infected Wound Models
Posted inDermatology Infectious Diseases news

Dual-Action IgY and Cerium Oxide Nanofibrous Dressings Accelerate Scarless Healing in Infected Wound Models

Researchers have developed a novel P/G@IYCe dressing combining yolk immunoglobulins and cerium oxide nanoparticles. This synergy effectively neutralizes bacterial pathogens and reactive oxygen species, facilitating rapid, high-quality skin regeneration and significantly reducing scar formation in infected full-thickness wound models.
Preexisting Antiviral Immunity and Allogeneic T-Cell Transfer: Redefining the Therapeutic Landscape of Progressive Multifocal Leukoencephalopathy
Posted inInfectious Diseases Neurology news

Preexisting Antiviral Immunity and Allogeneic T-Cell Transfer: Redefining the Therapeutic Landscape of Progressive Multifocal Leukoencephalopathy

Recent studies highlight the critical role of virus-specific T-cells in treating progressive multifocal leukoencephalopathy. Pre-existing T-cells predict superior responses to checkpoint inhibitors, while allogeneic T-cell transfer offers a promising rescue therapy for patients with profound immunodeficiency, significantly reducing viral loads and improving clinical outcomes.
High-Dose Influenza Vaccine Offers Superior Protection Against Hospitalization in Older Adults Regardless of Diabetes Status
Posted inDiabetes & Endocrinology Infectious Diseases news Public Health

High-Dose Influenza Vaccine Offers Superior Protection Against Hospitalization in Older Adults Regardless of Diabetes Status

A secondary analysis of the DANFLU-2 trial demonstrates that high-dose influenza vaccines significantly reduce cardiorespiratory and influenza-related hospitalizations in adults aged 65 and older, with consistent benefits observed in patients with diabetes, particularly those with a disease duration exceeding five years.